Hans‐Peter Tony

7.4k total citations · 1 hit paper
151 papers, 4.4k citations indexed

About

Hans‐Peter Tony is a scholar working on Rheumatology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Hans‐Peter Tony has authored 151 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Rheumatology, 71 papers in Immunology and 32 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Hans‐Peter Tony's work include Rheumatoid Arthritis Research and Therapies (50 papers), Monoclonal and Polyclonal Antibodies Research (32 papers) and T-cell and B-cell Immunology (26 papers). Hans‐Peter Tony is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (50 papers), Monoclonal and Polyclonal Antibodies Research (32 papers) and T-cell and B-cell Immunology (26 papers). Hans‐Peter Tony collaborates with scholars based in Germany, United States and Switzerland. Hans‐Peter Tony's co-authors include Thomas Dörner, Petra Roll, Joel M. Kremer, Antonio Sánchez, Edward Keystone, Emma Alecock, Ronald van Vollenhoven, Alain Cantagrel, Paul Emery and Martin Wilhelm and has published in prestigious journals such as The Journal of Experimental Medicine, The EMBO Journal and Blood.

In The Last Decade

Hans‐Peter Tony

149 papers receiving 4.3k citations

Hit Papers

IL-6 receptor inhibition with tocilizumab improves treatm... 2008 2026 2014 2020 2008 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
    2008 866 citations Hans‐Peter Tony et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hans‐Peter Tony Germany 32 2.1k 1.6k 866 803 685 151 4.4k
Christophe Richez France 37 2.2k 1.0× 2.4k 1.4× 737 0.9× 560 0.7× 552 0.8× 148 4.6k
Elliot Chartash United States 23 1.4k 0.7× 3.0k 1.8× 792 0.9× 1.5k 1.9× 566 0.8× 49 4.7k
Jennifer H. Anolik United States 41 3.7k 1.8× 2.5k 1.5× 686 0.8× 437 0.5× 1.5k 2.3× 89 6.1k
John J. Cush United States 31 1.6k 0.7× 2.5k 1.5× 461 0.5× 1.2k 1.4× 418 0.6× 59 4.3k
D. Close United States 15 1.2k 0.6× 1.5k 0.9× 362 0.4× 442 0.6× 807 1.2× 26 3.0k
Peter Junker Denmark 34 1.3k 0.6× 2.0k 1.2× 437 0.5× 620 0.8× 279 0.4× 180 4.0k
Eugen Feist Germany 39 2.3k 1.1× 2.5k 1.5× 535 0.6× 1.3k 1.6× 788 1.2× 202 5.7k
David Hagerty United States 19 1.6k 0.7× 1.3k 0.8× 380 0.4× 627 0.8× 470 0.7× 34 4.2k
Koichiro Ohmura Japan 35 1.9k 0.9× 1.8k 1.1× 514 0.6× 485 0.6× 611 0.9× 170 4.3k
Josef S. Smolen Austria 24 1.2k 0.6× 2.9k 1.8× 850 1.0× 966 1.2× 893 1.3× 37 5.3k

Countries citing papers authored by Hans‐Peter Tony

Since Specialization
Citations

This map shows the geographic impact of Hans‐Peter Tony's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans‐Peter Tony with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans‐Peter Tony more than expected).

Fields of papers citing papers by Hans‐Peter Tony

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans‐Peter Tony. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans‐Peter Tony. The network helps show where Hans‐Peter Tony may publish in the future.

Co-authorship network of co-authors of Hans‐Peter Tony

This figure shows the co-authorship network connecting the top 25 collaborators of Hans‐Peter Tony. A scholar is included among the top collaborators of Hans‐Peter Tony based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans‐Peter Tony. Hans‐Peter Tony is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Foldenauer, Ann Christina, Rieke Alten, Martin Aringer, et al.. (2022). Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA). Journal of Clinical Medicine. 11(24). 7316–7316. 1 indexed citations
3.
Schwaneck, Eva C., Regina Renner, Hans‐Peter Tony, et al.. (2021). Clonal expansion of large granular lymphocytes in patients with spondyloarthritis and psoriatic arthritis treated with TNFα inhibitors. Rheumatology International. 41(11). 1979–1986. 3 indexed citations
4.
5.
Krause, Andreas, Peer Aries, Christoph Fiehn, et al.. (2018). Rituximab in routine care of severe active rheumatoid arthritis. Zeitschrift für Rheumatologie. 78(9). 881–888. 9 indexed citations
6.
Tony, Hans‐Peter, Hendrik Schulze‐Koops, Klaus Krüger, et al.. (2017). Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re-Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: Safety and Immunogenicity Results from a Multicenter, Randomized, Double-Blind Study. Arthritis & Rheumatism. 2 indexed citations
7.
Wech, Tobias, et al.. (2016). Anti-CCP status determines the power Doppler oscillation pattern in rheumatoid arthritis: a prospective study. Rheumatology International. 36(12). 1671–1675. 4 indexed citations
8.
Roll, Patrice, et al.. (2012). Janus-Kinase-Hemmer. Zeitschrift für Rheumatologie. 71(6). 473–478. 1 indexed citations
9.
Roll, Petra, Khalid Muhammad, Stefan Kleinert, et al.. (2011). In vivo effects of the anti–interleukin‐6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis & Rheumatism. 63(5). 1255–1264. 78 indexed citations
10.
Bittner, Stefan, Nicole Bobak, Martin Feuchtenberger, et al.. (2011). Expression of K2P5.1 potassium channels on CD4+T lymphocytes correlates with disease activity in rheumatoid arthritis patients. Arthritis Research & Therapy. 13(1). R21–R21. 25 indexed citations
11.
Roll, Petra & Hans‐Peter Tony. (2009). Anti-CD20-Therapie bei rheumatoider Arthritis. Zeitschrift für Rheumatologie. 68(5). 370–379. 2 indexed citations
12.
Roll, Petra, Thomas Dörner, & Hans‐Peter Tony. (2008). Anti‐CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatment. Arthritis & Rheumatism. 58(6). 1566–1575. 143 indexed citations
13.
Palanichamy, Arumugam, et al.. (2008). Modulation of molecular imprints in the antigen‐experienced B cell repertoire by rituximab. Arthritis & Rheumatism. 58(12). 3665–3674. 19 indexed citations
14.
Feuchtenberger, Martin, Sabine Müller, Petra Roll, et al.. (2008). Frequency of Regulatory T Cells is Not Affected by Transient B CellDepletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis. The Open Rheumatology Journal. 2(1). 81–88. 26 indexed citations
15.
Wollenhaupt, J., R. Alten, Harald Burkhardt, et al.. (2006). [Current therapeutic strategy for rheumatoid arthritis].. PubMed. 148(42). 38–42; quiz 43. 3 indexed citations
16.
Reimer, Stanislaus, Hans‐Peter Tony, Doris Kraemer, et al.. (2006). Assessment of a case-based training system (d3web.Train) in rheumatology. Rheumatology International. 26(10). 942–948. 12 indexed citations
17.
Kneitz, C., Matthias Goebeler, & Hans‐Peter Tony. (2003). Systemischer Lupus erythematodes. Der Internist. 44(12). 1557–1574. 1 indexed citations
18.
Keberle, M., et al.. (2000). Assessment of microvascular changes in Raynaud's phenomenon and connective tissue disease using colour Doppler ultrasound. Lara D. Veeken. 39(11). 1206–1213. 34 indexed citations
19.
Schuh, Kai, Andris Avots, Hans‐Peter Tony, Edgar Serfling, & Christian Kneitz. (1996). Nuclear NF-ATp is a Hallmark of Unstimulated B Cells from B-CLL Patients. Leukemia & lymphoma. 23(5-6). 583–592. 37 indexed citations
20.
Schmidt, Enno, Boris C. Bastian, Reinhard Dummer, et al.. (1996). Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Archives of Dermatological Research. 288(7). 353–357. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christophe Richez Breakdown of academic impact, for papers by Elliot Chartash Breakdown of academic impact, for papers by Jennifer H. Anolik Breakdown of academic impact, for papers by John J. Cush Breakdown of academic impact, for papers by D. Close Breakdown of academic impact, for papers by Peter Junker Breakdown of academic impact, for papers by Eugen Feist Breakdown of academic impact, for papers by David Hagerty Breakdown of academic impact, for papers by Koichiro Ohmura Breakdown of academic impact, for papers by Josef S. Smolen
Rankless by CCL
2026